Social Cooperation as a Driver for a Social and Solidarity Focused Approach to the Circular Economy

The circular economy (CE) is currently a very widespread paradigm aimed at addressing the climate crisis. However, its notions seem often to be only focused on technical, industrial and economic growth-centric goals, without practically addressing social problems such as inequality and social exclusion. In this context, type B social cooperation (SC-B) emerges in the Italian context as a type of organisation explicitly aiming at addressing social issues. It has historically fulfilled this mandate by pioneering, among others, “circular” processes in the field of waste management. In doing so, it has consolidated a high level of organizational and management capacity, which has made it an exemplary model capable of innovating the CE discourse and including marginalized people while delivering high-quality environmental services. Through evidence gathered integrating different methods and sources (interviews with social cooperatives, literature review, case study research on filed actions), this paper aims to offer a reading of SC-B as a driver for promoting a social turn of CE and local development. Moving beyond waste management and towards waste reuse, SC-B could play an active role in creating local and regional waste transformation and upcycling chains, capable of creating new employment and inclusion opportunities as well as reducing environmental impacts by processing wastes directly in the territory, shortening their treatment chain

An Efficient Method for Vault Nanoparticle Conjugation with Finely Adjustable Amounts of Antibodies and Small Molecules

Vaults are eukaryotic ribonucleoproteins consisting of 78 copies of the major vault protein (MVP), which assemble into a nanoparticle with an about 60 nm volume-based size, enclosing other proteins and RNAs. Regardless of their physiological role(s), vaults represent ideal, natural hollow nanoparticles, which are produced by the assembly of the sole MVP. Here, we have expressed in Komagataella phaffi and purified an MVP variant carrying a C-terminal Z peptide (vault-Z), which can tightly bind an antibody’s Fc portion, in view of targeted delivery. Via surface plasmon resonance analysis, we could determine a 2.5 nM affinity to the monoclonal antibody Trastuzumab (Tz)/vault-Z 1:1 interaction. Then, we characterized the in-solution interaction via co-incubation, ultracentrifugation, and analysis of the pelleted proteins. This showed virtually irreversible binding up to an at least 10:1 Tz/vault-Z ratio. As a proof of concept, we labeled the Fc portion of Tz with a fluorophore and conjugated it with the nanoparticle, along with either Tz or Cetuximab, another monoclonal antibody. Thus, we could demonstrate antibody-dependent, selective uptake by the SKBR3 and MDA-MB 231 breast cancer cell lines. These investigations provide a novel, flexible technological platform that significantly extends vault-Z’s applications, in that it can be stably conjugated with finely adjusted amounts of antibodies as well as of other molecules, such as fluorophores, cell-targeting peptides, or drugs, using the Fc portion as a scaffold

Effect of formoterol, tiotropium, and their combination in patients with acute exacerbation of chronic obstructive pulmonary disease : A pilot study

The aim of our study was to evaluate the pharmacodynamic effects of 1- day treatment with formoterol, tiotropium and their combination in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Twenty-one (19 males, mean age 7278 years, mean FEV1 38714% of predicted values) patients with mild to moderate AECOPD were enrolled. Patients received formoterol (12 mg deliver via Modulites b.i.d.), tiotropium (18 mg dry powder capsules delivered via HandiHalers once daily), and their combination, in randomized sequence. Serial measurements of FEV1, FVC, IC, SpO2 and HR were performed over 24 h. Formoterol, tiotropium, and their combination significantly improved the area under curves (AUCs) for FEV1, FVC and IC over 12 and 24 h. The mean FEV1, FVC and IC AUC0 12 h and AUC0 24 h after formoterol and tiotropium combination were significantly higher than formoterol and tiotropium alone, whereas the differences between the two single drugs were not statistically significant. Formoterol, either alone or in combination with tiotropium, elicited a significantly faster onset of action, and combination elicited a greater maximum bronchodilation than both single drugs in terms of FEV1 and FVC. After 24 h the bronchodilating effect of the three treatments disappeared, with the exception of the combination on FEV1. The results of this study have documented that, although the time course of the effects of evaluated drugs differs significantly from that in stable COPD, with a shorter bronchodilation both for tiotropium and formoterol, these two long-acting bronchodilators appear to also be complementary in mild to moderate AECOP

Upper airway size is related to obesity and body fat distribution in women

The aim of this study is to analyze the relationships between obesity, fat distribution and pharyngeal transversal area in women. Cross-sectional areas of the pharynx at the oro-pharyngeal junction and at the glottis and mean pharyngeal area were measured by acoustic pharyngometry in 145 women (age 42.9 +/- 15.1 years; range 14-82 years). Body weight, waist, hip and neck circumferences, and sagittal abdominal diameter (SAD) were determined. Pharyngeal area at the oro-pharyngeal junction, measured both in orthostatic and in lying position, was negatively related to BMI, waist, hip and SAD. Mean pharyngeal area was negatively related to BMI and to SAD only in orthostatic position. No significant correlations were found between pharyngeal areas at the glottis and any anthropometric measurements. In multiple regression analysis, only SAD retained independent relationship with pharyngeal area at the level of the oro-pharyngeal junction in both the positions and with mean pharyngeal area in the orthostatic position. We demonstrated an inverse association between upper airways size and both adiposity and visceral fat distribution in women

Long-term outcomes of COVID-19 vaccination in patients with rare and complex connective tissue diseases: The ERN-ReCONNET VACCINATE study

Background: Vaccination is one of the most important measures to contain the COVID-19 pandemic, especially for frail patients. VACCINATE is a multicentre prospective observational study promoted by the European Reference Network on Rare and Complex Connective Tissue and Musculoskeletal Diseases (ERN ReCONNET) aimed at assessing the long-term outcomes of COVID-19 vaccination in patients with rare and complex connective tissue diseases (rcCTDs) in terms of efficacy and safety. Methods: Adult rcCTDs patients were eligible for recruitment. Demographic, clinical and vaccination data were collected at enrolment. Follow-up visits were scheduled 4, 12, 24, 36 and 48 weeks after completion of the first vaccination cycle; data on adverse events, disease exacerbations and the occurrence of new SARS-CoV-2 in- fections were collected at these time-points. Findings: 365 rcCTDs patients (87 % female, mean age 51.8 ± 14.6 years) were recruited. Overall, 200 patients (54.8 %) experienced at least one adverse event, generally mild and in most cases occurring early after the vaccination. During follow-up, 55 disease exacerbations were recorded in 39 patients (10.7 %), distributed over the entire observation period, although most frequently within 4 weeks after completion of the vaccination cycle. The incidence of new SARS-CoV-2 infections was 8.9 per 1000 person-months, with no cases within 12 weeks from vaccine administration and an increasing trend of infections moving away from the primary vaccination cycle. Only one case of severe COVID-19 was reported during the study period. Interpretation: COVID-19 vaccination seems effective and safe in rcCTDs patients. The rate of new infections was rather low and serious infections were uncommon in our cohort. No increased risk of disease flares was observed compared to previous disease history; however, such exacerbations may be potentially severe, emphasising the need for close monitoring of our patients

Can beta2-adrenoceptor agonists, anticholinergic drugs, and theophylline contribute to the control of pulmonary inflammation and emphysema in COPD?

Chronic obstructive pulmonary disease (COPD) has become a global epidemic disease with an increased morbidity and mortality in the world. Inflammatory process progresses and contributes to irreversible airflow limitation. However, there is no available therapy to better control the inflammatory progression and therefore to reduce the exacerbations and mortality. Thus, the development of efficient anti-inflammatory therapies is a priority for patients with COPD. beta(2) -Adrenoceptor agonists and anticholinergic agents are widely used as first line drugs in management of COPD because of their efficient bronchodilator properties. At present, many studies in vitro and some data obtained in laboratory animals reveal the potential anti-inflammatory effects of these bronchodilators but their protective role against chronic inflammation and the development of emphysema in patients with COPD remains to be investigated. The anti-inflammatory effects of theophylline at low doses have also been identified. Beneficial interactions between glucocorticoids and bronchodilators have been reported, and signaling pathways explaining these synergistic effects begin to be understood, especially for theophylline. Recent data demonstrating interactions between anticholinergics with beta(2) -adrenoceptor agonists aiming to better control the pulmonary inflammation and the development of emphysema in animal models of COPD justify the priority to investigate the interactive effects of a tritherapy associating corticoids with the two main categories of bronchodilators